Abstract 1358
Background
Atezolizumab, an ani-PD-L1 monoclonal antibody, has been used in the treatment of a wide variety of cancers. Recently, atezolizumab has shown significant antitumor activity against non-small cell lung cancer (NSCLC), the majority of lung cancer which is the leading cause of cancer-related mortality in both sexes. The purpose of our study is to consolidate the efficacy of atezolizumab in combination with chemotherapy for first-line treatment of advanced NSCLC.
Methods
We systematically conducted a comprehensive literature search using PUBMED, MEDLINE, EMBASE databases and meeting abstracts from inception through March 2019. RCTs utilizing first-line atezolizumab chemoimmunotherapy in patients with advanced NSCLC were incorporated. A generic inverse variance method was used to calculate the estimated pooled hazard ratio (HR) for overall survival (OS) and progression-free survival (PFS) with 95% confidence interval (CI). Heterogeneity was assessed with Cochran’s Q -statistic. Random effects model was applied.
Results
A total of 2725 patients with advanced NSCLC from four phase III RCTs (IMpower – 130, 131, 132 and 150) were eligible. The study arm used standard chemotherapy regimens in combination with atezolizumab while control arm used only standard chemotherapy regimens. The randomization ratio was 2:1 in IMpower130 study and 1:1 in other studies. IMpower131 study included patients with squamous histology and other studies were employed in patients with non-squamous NSCLC. The pooled HR for PFS was statistically significant at 0.64 (95% CI: 0.59-0.70; P < 0.00001) and the pooled HR for OS was 0.83 (95% CI: 0.75- 0.93; P = 0.0008). In non-squamous NSCLC histology group, the pooled HR for PFS was noted at 0.62 (95% CI: 0.56-0.69; P < 0.00001) and the pooled HR for OS was 0.79 (95% CI: 0.70- 0.90; P = 0.0002).
Conclusions
Our meta-analysis demonstrated that first-line atezolizumab in combination with chemotherapy significantly improved PFS and OS compared to standard chemotherapy in patients with advanced NSCLC, regardless of the histology.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4883 - A New Population Model Validated Pharmacokinetic Similarity of HLX01 and Rituximab in B-Cell Lymphoma
Presenter: Yuankai Shi
Session: Poster Display session 1
Resources:
Abstract
4908 - Efficacy of salvage therapy in the treatment of Helicobacter pylori-positive gastric low-grade mucosa-associated lymphoid tissue lymphoma
Presenter: Sung-Nam Lim
Session: Poster Display session 1
Resources:
Abstract
2360 - Mutational analysis of extranodal marginal zone lymphoma using next generation sequencing
Presenter: Seok Jae Huh
Session: Poster Display session 1
Resources:
Abstract
2430 - Clinical features, treatment and outcomes of colon and rectum mucosa-associated lymphoid tissue (MALT) lymphoma: Literature reviews published in English between 1993 and 2017
Presenter: Jeong Yeon Kim
Session: Poster Display session 1
Resources:
Abstract
4654 - Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 52 patients
Presenter: Guldane Cengiz Seval
Session: Poster Display session 1
Resources:
Abstract
1732 - Safety and efficacy of Bendamustine and Rituximab (BR) regimen in Indian Chronic Lymphocytic Leukemia patients
Presenter: Ajay Gogia
Session: Poster Display session 1
Resources:
Abstract
5784 - N-terminal B-type natriuretic peptide (NT-proBNP) as an independed prognostic marker for patients with newly diagnosed multiple myeloma complicated by dialysis-dependent renal failure
Presenter: Sergey Semochkin
Session: Poster Display session 1
Resources:
Abstract
836 - The first-line effect of Bortezomib-based Therapy on Clinical Outcomes for Taiwanese Patients with multiple myeloma
Presenter: Ching-Liang Ho
Session: Poster Display session 1
Resources:
Abstract
2085 - Impact of Donor Lymphocyte Infusion in Relapsing Myeloid Neoplasms Post Allogeneic Hematopoietic Stem Cell Transplantation
Presenter: Hanafy Hafez
Session: Poster Display session 1
Resources:
Abstract
6079 - Invasive fungal diseases in patients with Hodgkin’s lymphoma before and after allogeneic hematopoietic stem cell transplantation
Presenter: Marina Popova
Session: Poster Display session 1
Resources:
Abstract